Invivyd Announces New Clinical Trial to Assess VYD2311 for Long COVID

Summary

Invivyd, Inc. (Nasdaq: IVVD) has announced a new clinical study to evaluate monoclonal antibody therapy for Long COVID, focusing on its candidate VYD2311. The study design, proposed by the SPEAR Study Group, will be presented at the RECOVER-TLC Workshop on September 9-10, 2025, in Bethesda, Maryland. The aim is to maintain high antiviral antibody levels to combat chronic infection associated with Long COVID. Drs. Amy Proal and David Putrino will present the study details during the workshop.Reuters

Impact Analysis

So basically, Invivyd is doubling down on its monoclonal antibody VYD2311, now targeting Long COVID. This is really about expanding their market reach and addressing a significant unmet need. The timing is interesting, given their recent alignment with the FDA for a streamlined approval pathway for VYD2311 aimed at preventing COVID-19 Reuters. The market might be underestimating the potential here, especially with the upcoming presentation at the RECOVER-TLC Workshop Reuters. The recent $57.5 million raised through a public offering Reuters should provide the necessary funding to advance this program. However, execution risk remains high, and the market’s reaction to their stock offering shows some skepticism Sina Finance. I’d read this as a high-risk, high-reward scenario. If they can demonstrate efficacy in Long COVID, it could be a game-changer, not just for Invivyd but for the broader biotech sector.